Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics' stock has increased by 78.41% over the past six months, with a share price of $28.22 as of January 9, 2026, marking a 104.34% increase from January 10, 2025. Key events impacting the stock include a 30% surge following strong Q3 2025 earnings, FDA approvals and submissions for ZORYVE, the announcement of 2026 strategic priorities including full-year net product sales guidance of $455–$470 million and an anticipated transition to positive cash flows, a new board appointment in December 2025, and more insider selling than buying over the past three months, with Director Todd Watanabe completing the most substantial insider reduction.

Demand for Arcutis Biotherapeutics' products, particularly prescription topical products like ZORYVE, is subject to seasonality. The company anticipates a moderation in sequential growth rates in the third quarter, followed by a return to robust growth in the fourth quarter. Seasonality is also expected in the first quarter, often related to the resetting of insurance deductibles. A seasonal chart analysis suggests a historical "Buy Date of December 1 and a Sell Date of March 1" for ARQT stock, but this is based on insufficient data.

Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological diseases. The company's flagship product is ZORYVE (roflumilast), a phosphodiesterase-4 (PDE4) inhibitor, available in various formulations and indications, including ZORYVE cream 0.3% for plaque psoriasis, ZORYVE cream 0.15% for atopic dermatitis, ZORYVE cream 0.05% for atopic dermatitis in pediatric patients, and ZORYVE topical foam 0.3% for scalp and body psoriasis and seborrheic dermatitis. The company also has a pipeline of investigational products, including ARQ-154, ARQ-255, ARQ-252, and ARQ-234.

Arcutis Biotherapeutics is headquartered in Westlake Village, California, United States. The company's products have received regulatory approvals and are commercialized in the U.S. and Canada.

Arcutis Biotherapeutics maintains a positive brand reputation within the financial and medical communities. Analysts have a "Moderate Buy" consensus rating for the stock, and the company is viewed favorably compared to others in the medical sector. The successful commercialization and strong demand growth for ZORYVE have solidified its position as a leading branded non-steroidal topical treatment. The significant year-over-year increase in Q3 2025 net product revenue and the achievement of net income for the quarter also reflect positively on the company's performance and reputation.

Arcutis Biotherapeutics' ownership is primarily institutional, with approximately 72.44% of the stock held by institutional investors. Major institutional owners include Jennison Associates Llc, Rubric Capital Management LP, and BlackRock, Inc. Individual investors (insiders) own approximately 9.47% of the stock, with Patrick Heron owning the most shares among individual investors. Other significant insider holdings include Director Todd Watanabe, Officer Masaru Matsuda, and Officer Larry Todd Edwards.